公开(公告)号：US20170202960A1

公开(公告)日：2017-07-20

申请号：US15467660

申请日：2017-03-23

申请人： GLAXOSMITHKLINE BIOLOGICALS, SA

发明人： Luis Brito ,  Michelle Chan ,  Andrew Geall ,  Derek O'Hagan ,  Manmohan Singh

IPC分类号： A61K39/39 ,  A61K47/02 ,  A61K47/12 ,  C12N7/00 ,  A61K47/34 ,  A61K47/22 ,  A61K39/245 ,  A61K39/155 ,  A61K47/06 ,  A61K47/26

CPC分类号： A61K39/39 ,  A61K9/1075 ,  A61K39/12 ,  A61K39/155 ,  A61K39/245 ,  A61K47/02 ,  A61K47/06 ,  A61K47/12 ,  A61K47/22 ,  A61K47/24 ,  A61K47/26 ,  A61K47/34 ,  A61K2039/5256 ,  A61K2039/53 ,  A61K2039/55555 ,  A61K2039/55566 ,  A61K2039/575 ,  C12N7/00 ,  C12N2710/16134 ,  C12N2710/16171 ,  C12N2710/16734 ,  C12N2710/16771 ,  C12N2760/18534 ,  C12N2760/18571 ,  C12N2770/36134 ,  C12N2770/36143 ,  C12N2840/203 ,  Y02A50/386 ,  Y02A50/388 ,  Y02A50/412

摘要： This invention generally relates to cationic oil-in-water emulsions that contain high concentrations of cationic lipids and have a defined oil:lipid ratio. The cationic lipid can interact with the negatively charged molecule thereby anchoring the molecule to the emulsion particles. The cationic emulsions described herein are useful for delivering negatively charged molecules, such as nucleic acid molecules to cells, and for formulating nucleic acid-based vaccines.

公开(公告)号：US20160317650A1

公开(公告)日：2016-11-03

申请号：US15213662

申请日：2016-07-19

申请人： Pulike Biological Engineering, Inc.

发明人： Kegong TIAN ,  Xuke ZHANG ,  Jinzhong SUN ,  Feifei TAN

IPC分类号： A61K39/245 ,  A61K45/06 ,  C12N7/00

CPC分类号： A61K39/245 ,  A61K39/12 ,  A61K45/06 ,  A61K2039/5252 ,  A61K2039/5254 ,  A61K2039/543 ,  A61K2039/545 ,  A61K2039/552 ,  C12N7/00 ,  C12N7/04 ,  C12N2710/16011 ,  C12N2710/16634 ,  C12N2710/16721 ,  C12N2710/16734 ,  C12N2710/16762 ,  C12N2710/16771 ,  C12N2770/20071

摘要： The present invention provides an attenuated strain of porcine pseudorabies virus (PRV), in which said attenuated strain of PRV is a variant strain of PRV with inactivation of gI/gE/11K/28K proteins. In addition, the present invention also provides a vaccine composition comprising the attenuated strain of PRV as an antigen, a preparation method and use thereof. Proved by immunogenicity and pathogenicity testing of the live vaccine, said live PRV vaccine can provide a good protection for pigs with no clinical signs observed, indicating excellent immune protection.

公开(公告)号：US5858989A

公开(公告)日：1999-01-12

申请号：US682847

申请日：1996-07-10

申请人： Lorne Babiuk ,  Sylvia van der Hurk ,  Tim Zamb ,  David Fitzpatrick

发明人： Lorne Babiuk ,  Sylvia van der Hurk ,  Tim Zamb ,  David Fitzpatrick

IPC分类号： A61K39/00 ,  A61K39/245 ,  A61K39/295 ,  C07K14/035 ,  C07K14/06 ,  C12N15/38 ,  C12N15/861 ,  G01N33/68 ,  A61K48/00 ,  C07K14/03

CPC分类号： C07K14/005 ,  A61K39/12 ,  A61K39/245 ,  C12N15/86 ,  G01N33/6854 ,  A61K2039/53 ,  A61K2039/70 ,  A61K39/00 ,  C12N2710/10343 ,  C12N2710/14143 ,  C12N2710/16622 ,  C12N2710/16634 ,  C12N2710/16722 ,  C12N2710/16734 ,  C12N2710/16771 ,  C12N2710/24143 ,  C12N2830/30 ,  G01N2333/03

摘要： Recombinant subunit vaccines against bovine herpesvirus type 1 (BHV-1) are provided, as well as methods of vaccination and methods of recombinantly producing the subunit antigens or nucleotide sequences employed in the vaccines.

摘要翻译： 提供了针对牛疱疹病毒1型（BHV-1）的重组亚单位疫苗，以及接种方法和重组产生疫苗中使用的亚基抗原或核苷酸序列的方法。

公开(公告)号：US20240270796A1

公开(公告)日：2024-08-15

申请号：US18494219

申请日：2023-10-25

申请人： THE HENRY M. JACKSON FOUNDATION FOR THE ADVANCEMENT OF MILITARY MEDICINE, INC.

发明人： Xinle Cui ,  Clifford M. Snapper

IPC分类号： C07K14/005 ,  A61K39/245 ,  A61K39/25 ,  A61P31/22 ,  C12N7/00

CPC分类号： C07K14/005 ,  A61K39/245 ,  A61K39/25 ,  A61P31/22 ,  C12N7/00 ,  C12N2710/16034 ,  C12N2710/16071 ,  C12N2710/16134 ,  C12N2710/16171 ,  C12N2710/16234 ,  C12N2710/16271 ,  C12N2710/16334 ,  C12N2710/16371 ,  C12N2710/16634 ,  C12N2710/16671 ,  C12N2710/16734 ,  C12N2710/16771

摘要： Provided are antigenic compositions and uses thereof that include at least two human herpesvirus (HHV) polypeptides involved in mediating HHV binding, fusion, and entry into host cells, such as gp350, gH, gL, and gB, or nucleic acids encoding the polypeptides. The two HHV polypeptides comprise any combination of: a gB polypeptide; a gp350 polypeptide; a gL polypeptide; and a gH polypeptide, and optionally any one or more of the following polypeptides: gp42, gM, gN, gl, gC, gE, gD, ORF68, BMRF-2, BDLF2, UL128, UL130, UL131A, and gpK8.1. Also disclosed are methods of inducing an immune response or treating or preventing O an HHV infection in a subject by administering to the subject at least two of the HHV polypeptides or nucleic acid(s) encoding the same. Methods of passively transferring immunity using high-titer anti-HHV antibodies or immune cells are also disclosed.

公开(公告)号：US11643441B1

公开(公告)日：2023-05-09

申请号：US15767587

申请日：2016-10-21

申请人： ModernaTX, Inc.

发明人： Giuseppe Ciaramella ,  Sayda Mahgoub Elbashir

IPC分类号： C07K14/005 ,  A61K39/25 ,  A61K9/51 ,  A61K9/00 ,  A61K39/00

CPC分类号： C07K14/005 ,  A61K9/0019 ,  A61K9/5123 ,  A61K39/25 ,  A61K2039/53 ,  A61K2039/54 ,  A61K2039/545 ,  A61K2039/575 ,  A61K2039/70 ,  C12N2710/16722 ,  C12N2710/16734 ,  C12N2710/16771

摘要： Aspects of the disclosure relate to nucleic acid vaccines. The vaccines include at least one RNA polynucleotides having an open reading frame encoding at least one varicella zoster virus (VZV) antigen. Methods for preparing and using such vaccines are also described.

公开(公告)号：US20160114029A1

公开(公告)日：2016-04-28

申请号：US14980673

申请日：2015-12-28

申请人： PULIKE BIOLOGICAL ENGINEERING, INC.

发明人： XUKE ZHANG ,  JINZHONG SUN ,  RUI WU ,  FEIFEI TAN ,  CHAOYONG BAI ,  KEGONG TIAN

IPC分类号： A61K39/245 ,  C12N7/00 ,  C07K14/005

CPC分类号： C07K14/005 ,  A61K39/00 ,  A61K39/12 ,  A61K39/245 ,  A61K2039/5252 ,  A61K2039/552 ,  C07H21/04 ,  C12N7/00 ,  C12N7/04 ,  C12N2710/16721 ,  C12N2710/16722 ,  C12N2710/16734 ,  C12N2710/16761 ,  C12N2710/16771

摘要： Provided in the embodiments of the present invention is a vaccine composition including an immune amount of attenuated live vaccine, inactivated vaccine, subunit vaccine, synthetic vaccine, or genetically engineered vaccine of the porcine pseudorabies virus strain. The vaccine composition can effectively induce antibody generation, and prevent infections of virulent strains of the porcine pseudorabies virus, and provides effective protection for pigs.

摘要翻译： 在本发明的实施方案中提供了包含免疫量的减毒活疫苗，灭活疫苗，亚单位疫苗，合成疫苗或猪伪狂犬病病毒株的遗传工程化疫苗的疫苗组合物。 疫苗组合物可以有效地诱导抗体产生，并防止猪伪狂犬病病毒毒株的感染，并为猪提供有效的保护。

公开(公告)号：US08877211B2

公开(公告)日：2014-11-04

申请号：US13325182

申请日：2011-12-14

申请人： Shafiqul I. Chowdhury ,  Hui Yong Wei

发明人： Shafiqul I. Chowdhury ,  Hui Yong Wei

IPC分类号： A61K39/245 ,  C12N15/63 ,  C12N7/01 ,  A61P31/22 ,  C12N7/00 ,  A61K39/00

CPC分类号： A61K39/245 ,  A61K39/12 ,  A61K2039/5254 ,  A61K2039/552 ,  A61K2039/57 ,  C12N7/00 ,  C12N2710/16734 ,  C12N2710/16762 ,  C12N2710/16771

摘要： A BHV-1 mutant virus has been made that incorporates into a single virus two or more deletions in one or more of three genes—glycoprotein N, glycoprotein E and Us9. Specifically, a BHV-1 UL49.5Δ30-32 CT-null virus was made and tested. This mutant virus was then used to incorporate additional changes, e.g., the glycoprotein E cytoplasmic-tail deletion, the Us9 deletion, or both. This triple mutant BHV-1 UL49.5Δ30-32 CT-null/gE CTΔ/Us9Δ virus will be superior to the current BHV-1 mutants because the mutant virus will not be shed following reactivation, will be a DIVA based on gE CT-specific serum antibodies, and will induce better protective response by inducing higher SN titers and better cellular immune response. This new virus will have sufficient viral replication in the nasal epithelium and will be a good vaccine for protection of cattle from BHV-1. The new mutant viruses can also be used as vectors for exogenous genes.

摘要翻译： 已经制备了一种BHV-1突变病毒，其在一个或多个三个基因 - 糖蛋白N，糖蛋白E和Us9中的一个或多个中包含单个病毒两个或多个缺失。 具体来说，制造并测试了BHV-1 UL49.5＆Dgr; 30-32 CT-无效病毒。 然后将该突变型病毒用于引入额外的变化，例如糖蛋白E细胞质尾缺失，Us9缺失或两者。 这种三重突变体BHV-1 UL49.5＆Dgr; 30-32 CT-null / gE CT＆Dgr; / Us9＆Dgr; 病毒将优于目前的BHV-1突变体，因为突变型病毒在再激活后不会脱落，将是基于gE CT特异性血清抗体的DIVA，并通过诱导较高的SN滴度和更好的细胞免疫来诱导更好的保护性反应 响应。 这种新病毒将在鼻上皮中具有足够的病毒复制，并且将是用于保护牛从BHV-1的良好疫苗。 新的突变病毒也可以用作外源基因的载体。

公开(公告)号：US20180021424A1

公开(公告)日：2018-01-25

申请号：US15213627

申请日：2016-07-19

申请人： Zoetis Services LLC

发明人： Paul Joseph Dominowski ,  Duncan Mwangi ,  Sharath K. Rai ,  Dennis L. Foss ,  Traci K. Godbee ,  Laurel Mary Sly ,  Suman Mahan ,  Shaunak Vora

IPC分类号： A61K39/12 ,  A61K39/39 ,  A61K39/145 ,  C12N7/00 ,  A61K39/002 ,  C12N15/117 ,  A61K39/265

CPC分类号： A61K39/12 ,  A61K39/012 ,  A61K39/39 ,  A61K2039/5252 ,  A61K2039/552 ,  A61K2039/55555 ,  A61K2039/55561 ,  A61K2039/70 ,  C12N7/00 ,  C12N2710/16734 ,  C12N2710/16771 ,  C12N2760/16134 ,  C12N2760/16171 ,  C12N2770/24034 ,  C12N2770/24334 ,  C12N2770/24371

摘要： The invention provides a liposomal adjuvant composition comprising an external membrane and an internal compartment, the external membrane comprising: a quaternary ammonium compound; a sterol; a phospholipid; and a glycolipid. Vaccine compositions comprising the liposomal adjuvant of the instant invention are also provided.

公开(公告)号：US09636410B2

公开(公告)日：2017-05-02

申请号：US14130886

申请日：2012-07-06

申请人： Luis Brito ,  Michelle Chan ,  Andrew Geall ,  Derek O'Hagan ,  Manmohan Singh

发明人： Luis Brito ,  Michelle Chan ,  Andrew Geall ,  Derek O'Hagan ,  Manmohan Singh

IPC分类号： A61K47/48 ,  A61K9/107 ,  A61K47/06 ,  A61K47/24 ,  A61K39/12 ,  A61K39/39 ,  A61K39/00

CPC分类号： A61K39/39 ,  A61K9/1075 ,  A61K39/12 ,  A61K39/155 ,  A61K39/245 ,  A61K47/02 ,  A61K47/06 ,  A61K47/12 ,  A61K47/22 ,  A61K47/24 ,  A61K47/26 ,  A61K47/34 ,  A61K2039/5256 ,  A61K2039/53 ,  A61K2039/55555 ,  A61K2039/55566 ,  A61K2039/575 ,  C12N7/00 ,  C12N2710/16134 ,  C12N2710/16171 ,  C12N2710/16734 ,  C12N2710/16771 ,  C12N2760/18534 ,  C12N2760/18571 ,  C12N2770/36134 ,  C12N2770/36143 ,  C12N2840/203 ,  Y02A50/386 ,  Y02A50/388 ,  Y02A50/412

摘要： This invention generally relates to cationic oil-in-water emulsions that contain high concentrations of cationic lipids and have a defined oil:lipid ratio. The cationic lipid can interact with the negatively charged molecule thereby anchoring the molecule to the emulsion particles. The cationic emulsions described herein are useful for delivering negatively charged molecules, such as nucleic acid molecules to cells, and for formulating nucleic acid-based vaccines.

公开(公告)号：US20170065715A1

公开(公告)日：2017-03-09

申请号：US15354233

申请日：2016-11-17

申请人： GLAXOSMITHKLINE BIOLOGICALS S.A.

发明人： Pierre VANDEPAPELIERE

IPC分类号： A61K39/39 ,  A61K39/102 ,  A61K39/104

CPC分类号： A61K39/39 ,  A61K39/00 ,  A61K39/015 ,  A61K39/092 ,  A61K39/102 ,  A61K39/1045 ,  A61K39/12 ,  A61K39/145 ,  A61K2039/5258 ,  A61K2039/545 ,  A61K2039/55 ,  A61K2039/55505 ,  A61K2039/55555 ,  A61K2039/55572 ,  A61K2039/55577 ,  A61K2039/57 ,  A61K2039/6037 ,  A61K2039/6068 ,  A61K2039/70 ,  C12N2710/10134 ,  C12N2710/16134 ,  C12N2710/16171 ,  C12N2710/16734 ,  C12N2710/16771 ,  C12N2710/20071 ,  C12N2730/10134 ,  C12N2760/16134 ,  C12N2760/16171 ,  C12N2760/16234 ,  C12N2760/16271 ,  C12N2760/20034 ,  Y02A50/412

摘要： The present invention provides a human dose of an immunogenic composition comprising an antigen or antigenic preparation, in combination with an adjuvant which adjuvant comprises an immunologically active saponin fraction derived from the bark of Quillaja Saponaria Molina presented in the form of a liposome and a lipopolysaccharide wherein said saponin fraction and said lipopolysaccharide are both present in said human dose at a level of below 30 μg. The present invention further provides an adjuvant composition in a human dose suitable volume comprising between 1 and 30 μg of a lipopolysaccharide and between 1 and 30 μg of an immunologically active saponin fraction presented in the form of a liposome.

摘要翻译： 本发明提供人剂量的免疫原性组合物，其包含与佐剂组合的抗原或抗原制剂，所述佐剂包含衍生自脂质体形式的Quillaja Saponaria Molina的树皮的免疫学活性皂苷级分和脂多糖，其中 所述皂苷部分和所述脂多糖均以所述人类剂量存在，水平低于30μg。 本发明还提供了一种人体剂量合适体积的佐剂组合物，其包含1至30μg脂多糖和1至30μg以脂质体形式存在的免疫学活性皂苷级分。